Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

18F-AV-1451 (F 18 T807)

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Tau
Use
Prognostic
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Target Population/ Population Being Studied

Patients with Primary Progressive Aphasia With Suspected Alzheimer's Disease

Length of Current Trial
2 years
Number of Trial Participants

70

Estimated Trial Completion
February 2022
What is Required from Patients

injection of radioactive tracers, mild discomfort, in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes

Sponsor

Northwestern University; National Institute on Aging (NIA)

  1. “Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans (ADRC proj 1).” ClinicalTrials.gov. Accessed October 9, 2020. https://clinicaltrials.gov/ct2/show/NCT03287765?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=9

  2. “F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD).” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT02414178?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=5

  3. “F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND).” ClinicalTrials.gov. Accessed October 9, 2020. https://clinicaltrials.gov/ct2/show/NCT02414347?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=9&rank=79

  4. “F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E).” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT02414282?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=10&rank=88

  5. “Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS).”ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03507257?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=3

  6. “Tau PET Imaging in Atypical Dementias.” ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03283449?term=18F-AV-1451&recrs=adf&cond=alzheimers&rank=10